NAPLEX Quiz: Sterile Preparations
20 questions · exam conditions
0:00
Sterile PreparationsQuestion 1 of 20

A 6-year-old male (20 kg) with acute lymphoblastic leukemia is scheduled for vincristine 1.2 mg IV today (hazardous drug). Allergies: none. Labs: SCr 0.4 mg/dL, AST 20 units/L, ALT 16 units/L, WBC 2,100/mm3^3, platelets 85,000/mm3^3. Current medications: trimethoprim-sulfamethoxazole 80/400 mg by mouth twice daily on weekends, ondansetron 4 mg by mouth every 8 hours as needed. The dose will be compounded in a negative-pressure ISO Class 7 hazardous buffer room using an ISO Class 5 biological safety cabinet (BSC) and transported to the infusion center. Which personal protective equipment is required for this preparation?

One pair of sterile chemotherapy gloves and a surgical mask; gown optional if working in a BSC
Two pairs of chemotherapy gloves and a chemotherapy gown; add eye/face protection if splash risk exists
One pair of sterile gloves and a hair cover only, because the PEC provides product and personnel protection
N95 respirator only, because vincristine is primarily a vapor hazard
← Back to quizzes

NAPLEX Quiz

NAPLEX Quiz: Sterile Preparations

Practice Sterile Preparations in NAPLEX with focused quiz questions that help you check what you know, review explanations, and build confidence with test-style prompts.

What this quiz covers

This quiz focuses on Sterile Preparations, giving you a quick way to practice the rules, question types, and explanations that matter most for NAPLEX.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

All questions

Question 1

A 6-year-old male (20 kg) with acute lymphoblastic leukemia is scheduled for vincristine 1.2 mg IV today (hazardous drug). Allergies: none. Labs: SCr 0.4 mg/dL, AST 20 units/L, ALT 16 units/L, WBC 2,100/mm3^3, platelets 85,000/mm3^3. Current medications: trimethoprim-sulfamethoxazole 80/400 mg by mouth twice daily on weekends, ondansetron 4 mg by mouth every 8 hours as needed. The dose will be compounded in a negative-pressure ISO Class 7 hazardous buffer room using an ISO Class 5 biological safety cabinet (BSC) and transported to the infusion center. Which personal protective equipment is required for this preparation?

  1. One pair of sterile chemotherapy gloves and a surgical mask; gown optional if working in a BSC
  2. Two pairs of chemotherapy gloves and a chemotherapy gown; add eye/face protection if splash risk exists (correct answer)
  3. One pair of sterile gloves and a hair cover only, because the PEC provides product and personnel protection
  4. N95 respirator only, because vincristine is primarily a vapor hazard

Explanation: The concept being tested is personal protective equipment (PPE) requirements for handling hazardous drugs under USP <800>. The key factor is the hazardous nature of vincristine, requiring enhanced protection during compounding in a biological safety cabinet (BSC) for the pediatric leukemia patient. Choice B is the best because two pairs of chemotherapy gloves and a chemotherapy gown provide barrier protection against exposure, with eye/face protection added for splash risks, ensuring personnel and patient safety. Choice A is incorrect as one pair of gloves and optional gown underestimate hazardous drug risks, even in a BSC, leading to potential contamination. Choices C and D are suboptimal because minimal gloves/hair cover ignore full PPE needs, and N95 is for airborne hazards not primary for vincristine, common errors in hazardous compounding. A transferable pearl is to always use USP <800>-compliant PPE for hazardous drugs, including double gloving and dedicated gowns. Proper aseptic technique involves maintaining negative pressure in hazardous buffer rooms to contain contaminants.

Question 2

A 76-year-old male (74 kg) with sepsis is ordered norepinephrine 8 mg in 250 mL D5W as a continuous IV infusion. Allergies: none. Labs: SCr 1.8 mg/dL, AST 40 units/L, ALT 33 units/L, WBC 19,000/mm3^3. Current medications: vasopressin infusion, meropenem 1 g IV every 8 hours. The pharmacy will batch compound multiple norepinephrine bags for the ICU using an ISO Class 5 PEC in an ISO Class 7 buffer room, and store them refrigerated until needed. What is the appropriate beyond-use date for this compound?

  1. 24 hours refrigerated because it is a low-risk CSP
  2. 48 hours refrigerated because it is a low-risk CSP (correct answer)
  3. 7 days refrigerated because it is compounded in an ISO Class 7 buffer room
  4. 28 days refrigerated because norepinephrine is chemically stable

Explanation: The concept being tested is beyond-use date (BUD) assignment for batched low-risk compounded sterile preparations (CSPs) stored refrigerated. The key factor is the batch compounding of norepinephrine infusions in an ISO Class 5 PEC for ICU use in a septic patient. Choice B is the best because 48 hours refrigerated fits low-risk CSP guidelines for batched items, balancing stability and safety. Choice A is incorrect as 24 hours underestimates allowable time, potentially increasing workload. Choices C and D are suboptimal because 7 or 28 days exceed low-risk limits without testing, risking degradation. A transferable pearl is to protect light-sensitive drugs like norepinephrine during storage. Proper aseptic technique includes using friction when disinfecting with 70% isopropyl alcohol.

Question 3

A 3-day-old premature neonate (1.2 kg) in the neonatal intensive care unit requires a customized total parenteral nutrition (TPN) bag. Allergies: none. Labs: SCr 0.6 mg/dL, AST 35 units/L, ALT 18 units/L, total bilirubin 6.2 mg/dL, WBC 9,500/mm3^3, potassium 3.4 mEq/L, magnesium 1.6 mg/dL, phosphate 3.0 mg/dL. Current medications: ampicillin 50 mg/kg IV every 12 hours, gentamicin 4 mg/kg IV every 24 hours. The TPN will be compounded in an ISO Class 5 PEC within an ISO Class 7 buffer room and includes calcium gluconate and sodium phosphate additives. What is the most critical step in preparing this sterile product?

  1. Add calcium gluconate and sodium phosphate early and simultaneously to minimize compounding time
  2. Verify calcium and phosphate compatibility and add them in an order that reduces precipitation risk (typically phosphate first, calcium later) (correct answer)
  3. Use 0.9% sodium chloride as the primary diluent to reduce precipitation of calcium phosphate
  4. Filter the final TPN through a 5-micron filter to remove precipitates before dispensing

Explanation: The concept being tested is preventing incompatibility in total parenteral nutrition (TPN) compounding. The key factor is the risk of calcium phosphate precipitation in the customized TPN for a premature neonate with specific electrolyte needs. Choice B is the best because verifying compatibility and adding phosphate first then calcium minimizes precipitation, ensuring solution stability and patient safety. Choice A is incorrect as adding them simultaneously increases precipitation risk, a common error in hurried compounding. Choices C and D are suboptimal because sodium chloride may not prevent issues, and filtering does not address root causes, potentially clogging lines. A transferable pearl is to use compatibility charts and sequential addition for electrolytes in TPN. Proper PPE includes sterile gloves and gowns in the buffer room to maintain asepsis.

Question 4

A 45-year-old male (95 kg) with methicillin-resistant Staphylococcus aureus (MRSA) bacteremia is ordered daptomycin 600 mg IV now. Allergies: none. Labs: SCr 1.3 mg/dL, creatine kinase 110 units/L, AST 24 units/L, ALT 19 units/L, WBC 14,200/mm3^3. Current medications: atorvastatin 40 mg by mouth nightly, normal saline at 100 mL/hour. The dose is compounded from a single-dose vial, diluted in 50 mL of 0.9% sodium chloride, and will be stored at room temperature on the unit for administration during rounds. What is the appropriate beyond-use date for this compound?

  1. 1 hour at room temperature because it is an urgent dose
  2. 12 hours at controlled room temperature because it is a low-risk CSP (correct answer)
  3. 24 hours at controlled room temperature because it is a low-risk CSP
  4. 14 days refrigerated because it was prepared from a sterile vial

Explanation: The concept being tested is assigning beyond-use dates (BUDs) for low-risk compounded sterile preparations (CSPs) stored at room temperature. The key factor is the room temperature storage of the daptomycin infusion prepared from a single-dose vial for a patient with MRSA bacteremia. Choice B is the best because 12 hours at controlled room temperature matches low-risk CSP guidelines, preventing microbial growth and ensuring safety for prompt administration. Choice A is incorrect as 1 hour is for immediate-use only, not applicable here, leading to unnecessary waste. Choices C and D are suboptimal because 24 hours or 14 days exceed low-risk limits for room temperature, risking contamination, common errors in BUD miscalculation. A transferable pearl is to consider drug-specific stability alongside USP <797> risk levels when assigning BUDs. Proper aseptic technique requires avoiding contact with critical sites and using sterile 70% isopropyl alcohol for disinfection.

Question 5

A 72-year-old female (60 kg) with atrial fibrillation and inability to take oral medications is ordered amiodarone 150 mg IV in 100 mL of 5% dextrose (D5W) to infuse over 10 minutes. Allergies: none. Labs: SCr 1.0 mg/dL, AST 44 units/L, ALT 51 units/L, WBC 7,800/mm3^3. Current medications: heparin infusion per protocol, metoprolol 5 mg IV as needed. The pharmacy will compound the infusion in an ISO Class 5 PEC in an ISO Class 7 buffer room and send it immediately to the ICU. Which environmental condition is crucial for this preparation?

  1. Compounding must occur in an ISO Class 8 room as long as the product is used within 1 hour
  2. An ISO Class 5 PEC with HEPA-filtered unidirectional airflow must be used for critical sites and components (correct answer)
  3. A positive-pressure hazardous buffer room is required for all IV admixtures to prevent contamination
  4. A laminar airflow workbench may be placed in a nonclassified area if the surface is disinfected between doses

Explanation: The concept being tested is environmental controls required for sterile compounding under USP <797>. The key factor is the need for ISO-classified airflow to protect critical sites during preparation of amiodarone infusion for a patient unable to take oral medications. Choice B is the best because an ISO Class 5 PEC with HEPA-filtered unidirectional airflow safeguards components from contamination, ensuring sterile integrity and patient safety in the ICU. Choice A is incorrect as ISO Class 8 alone does not provide adequate protection, even for short use, risking microbial introduction. Choices C and D are suboptimal because positive-pressure hazardous rooms are for containment not non-hazardous drugs, and nonclassified areas violate standards, common errors in environmental setup. A transferable pearl is to certify PECs every 6 months for airflow and particle counts. Proper PPE guidelines include shoe covers, hair covers, and sterile gloves in the buffer room.

Question 6

A 65-year-old female (59 kg) is receiving ganciclovir 5 mg/kg IV every 12 hours for cytomegalovirus infection (hazardous drug per many institutional policies). Allergies: none. Labs: SCr 1.6 mg/dL, AST 28 units/L, ALT 26 units/L, WBC 2,400/mm3^3. Current medications: tacrolimus, mycophenolate, prednisone. The pharmacy compounds ganciclovir doses in an ISO Class 5 PEC located in a negative-pressure hazardous buffer room and uses hazardous drug labeling for transport. Which personal protective equipment is required for this preparation?

  1. One pair of sterile gloves only, because ganciclovir is not an antineoplastic
  2. Two pairs of chemotherapy gloves and a chemotherapy gown; add eye/face protection if splash risk exists (correct answer)
  3. No gloves are required if compounding occurs in an ISO Class 5 PEC
  4. Surgical mask and hair cover only, because dermal exposure is not a concern

Explanation: The sterile preparation concept being tested is the personal protective equipment (PPE) required for compounding non-antineoplastic hazardous drugs like ganciclovir in a hazardous drug setting. The key preparation-specific factor is that ganciclovir is classified as hazardous due to reproductive risks per NIOSH and institutional policies, necessitating handling in a negative-pressure hazardous buffer room. Choice B is the best choice for ensuring sterile integrity and patient safety because it requires two pairs of chemotherapy gloves and a chemotherapy gown to prevent dermal exposure to hazardous residues, with added eye/face protection for splash risks, aligning with USP <800> for HDs. Choice A is incorrect because, despite not being antineoplastic, ganciclovir's hazardous status demands full PPE, not just sterile gloves, to avoid exposure errors; choice C is suboptimal as gloves are mandatory for all aseptic HD compounding to maintain barriers, even in an ISO Class 5 PEC; choice D is wrong because it ignores glove and gown needs, focusing on less critical areas while dermal contact remains a primary concern. A transferable sterile compounding pearl is to review the NIOSH hazardous drug list and perform risk assessments for each agent to tailor PPE appropriately. Frameworks like USP <800> emphasize combining PPE with engineering controls, such as PECs in buffer rooms, and proper technique to safeguard personnel and preparations.

Question 7

A 29-year-old female (62 kg) with Crohn disease is ordered ustekinumab 390 mg IV induction dose. Allergies: none. Labs: SCr 0.7 mg/dL, AST 18 units/L, ALT 16 units/L, WBC 6,700/mm3^3. Current medications: prednisone 20 mg by mouth daily, pantoprazole 40 mg by mouth daily. The biologic will be prepared as an IV infusion in an ISO Class 5 PEC within an ISO Class 7 buffer room and administered later the same day. Which environmental condition is crucial for this preparation?

  1. An ISO Class 5 PEC is required to provide unidirectional HEPA-filtered airflow over critical sites during compounding (correct answer)
  2. An ISO Class 9 room is acceptable if the infusion is administered within 2 hours
  3. A negative-pressure room is required for all monoclonal antibodies because they are hazardous
  4. A segregated compounding area without ISO classification is acceptable if the vial is preservative-free

Explanation: The concept being tested is environmental requirements for biologic sterile preparations. The key factor is the need for controlled airflow during ustekinumab infusion preparation for the Crohn disease patient. Choice A is the best because an ISO Class 5 PEC provides essential HEPA-filtered air over critical sites, ensuring sterility and safety. Choice B is incorrect as ISO Class 9 lacks sufficient control, even for short use, risking particulates. Choices C and D are suboptimal because negative pressure is for hazardous drugs, and segregated areas limit BUDs unnecessarily. A transferable pearl is to monitor pressure differentials daily in cleanroom suites. Proper aseptic technique avoids rapid movements that disrupt airflow.

Question 8

A 52-year-old male (100 kg) with diabetic ketoacidosis is ordered an insulin infusion prepared as regular insulin 100 units in 100 mL of 0.9% sodium chloride. Allergies: none. Labs: SCr 1.0 mg/dL, potassium 5.6 mEq/L, bicarbonate 12 mEq/L, WBC 12,300/mm3^3. Current medications: potassium replacement per protocol, normal saline boluses. The infusion is compounded in an ISO Class 5 PEC in an ISO Class 7 buffer room and will be hung immediately. Which technique ensures sterility in this preparation?

  1. Use a sterile alcohol pad to disinfect the bag's injection port and allow it to dry before injecting insulin (correct answer)
  2. Disinfect the injection port after injecting insulin to prevent backflow contamination
  3. Use tap water to rinse gloves if they become sticky during compounding
  4. Remove needle caps by touching the needle hub to stabilize the cap during removal

Explanation: The concept being tested is aseptic techniques for insulin infusion compounding. The key factor is disinfecting the IV bag port before injecting insulin for the diabetic ketoacidosis patient. Choice A is the best because using sterile alcohol and allowing drying kills microbes, preventing contamination and ensuring infusion safety. Choice B is incorrect as post-injection disinfection does not prevent initial entry of contaminants. Choices C and D are suboptimal because tap water or touching hubs breaches sterility, common technique errors. A transferable pearl is to use luer-lock connections to secure infusions. Proper PPE guidelines prohibit jewelry in compounding areas to reduce bioburden.

Question 9

A 41-year-old male (76 kg) with bacterial meningitis is ordered ceftriaxone 2 g IV every 12 hours; the next dose is needed in 30 minutes. Allergies: none. Labs: SCr 0.8 mg/dL, AST 20 units/L, ALT 22 units/L, WBC 18,600/mm3^3. Current medications: dexamethasone 10 mg IV every 6 hours, acetaminophen 650 mg by mouth as needed. The pharmacy plans to compound a ceftriaxone minibag in a segregated compounding area (SCA) using an ISO Class 5 PEC because the buffer room is temporarily unavailable; the dose will be administered immediately after preparation. Which environmental condition is crucial for this preparation?

  1. Compounding in an SCA is acceptable if an ISO Class 5 PEC is used and the CSP is assigned a shorter beyond-use date per USP <797> (correct answer)
  2. Compounding in an SCA is prohibited under all circumstances; the dose must be prepared on the nursing unit
  3. A positive-pressure ISO Class 7 buffer room is required even for immediate administration
  4. An ISO Class 8 anteroom alone is sufficient if the PEC is disinfected before use

Explanation: The concept being tested is use of segregated compounding areas (SCAs) for urgent sterile preparations. The key factor is the temporary unavailability of the buffer room, necessitating SCA use for immediate ceftriaxone administration in meningitis. Choice A is the best because SCA with ISO Class 5 PEC allows compounding with shortened BUD per USP <797>, ensuring timely therapy and safety. Choice B is incorrect as SCA is permitted for Category 1 CSPs, not prohibited. Choices C and D are suboptimal because requiring buffer rooms or anterooms ignores SCA provisions, delaying care. A transferable pearl is to assign 12-hour RT BUD for Category 1 CSPs in SCAs. Proper framework includes daily cleaning of PECs in SCAs.

Question 10

A 34-year-old female (64 kg) is ordered methotrexate 25 mg intrathecal (hazardous drug) for leukemia. Allergies: none. Labs: SCr 0.6 mg/dL, AST 22 units/L, ALT 18 units/L, WBC 1,900/mm3^3. Current medications: leucovorin per protocol, acyclovir prophylaxis. The dose will be prepared in an ISO Class 5 BSC in a negative-pressure ISO Class 7 hazardous buffer room and dispensed in a syringe with a needleless cap. Which personal protective equipment is required for this preparation?

  1. Two pairs of chemotherapy gloves, chemotherapy gown, and head/hair cover; add eye/face protection if splash risk exists (correct answer)
  2. One pair of sterile gloves and a sterile gown only, because the product is administered intrathecally
  3. Surgical mask only, because the BSC provides adequate protection from hazardous drugs
  4. One pair of chemotherapy gloves and no gown to reduce shedding in the PEC

Explanation: The concept being tested is PPE requirements for hazardous intrathecal preparations under USP <800>. The key factor is the hazardous status of methotrexate, necessitating full protection for intrathecal compounding in a BSC. Choice A is the best because two pairs of chemotherapy gloves, gown, and head cover prevent exposure, with eye protection for splashes, ensuring safety for the leukemia patient. Choice B is incorrect as non-chemotherapy PPE underprotects against hazardous residues. Choices C and D are suboptimal because mask alone or single gloves ignore comprehensive needs, common PPE errors. A transferable pearl is to doff outer gloves before exiting the buffer room. Proper framework includes annual competency assessments for hazardous compounding.

Question 11

A 56-year-old female (65 kg) with rheumatoid arthritis is ordered tocilizumab 480 mg IV. Allergies: none. Labs: SCr 0.8 mg/dL, AST 48 units/L, ALT 55 units/L, WBC 3,600/mm3^3. Current medications: methotrexate 15 mg by mouth weekly, folic acid 1 mg by mouth daily, prednisone 5 mg by mouth daily. The infusion will be compounded in an ISO Class 5 PEC within an ISO Class 7 buffer room and delivered to an outpatient infusion suite. Which technique ensures sterility in this preparation?

  1. Disinfect the vial stopper and the IV bag port with sterile 70% isopropyl alcohol using friction and allow to dry before each access (correct answer)
  2. Use nonsterile gloves if hands were washed within the last hour to reduce glove changes
  3. Keep partially used syringes for later doses as long as they remain in the buffer room
  4. Touch the sterile needle to the IV bag port to align the puncture site before disinfecting

Explanation: The concept being tested is disinfection techniques for multi-component sterile infusions. The key factor is repeated access to vial and bag ports during tocilizumab compounding for the rheumatoid arthritis patient. Choice A is the best because friction with 70% isopropyl alcohol and drying before access prevents microbial entry, ensuring infusion sterility and safety. Choice B is incorrect as nonsterile gloves compromise asepsis, a common garbing error. Choices C and D are suboptimal because keeping used syringes or touching ports introduces contaminants. A transferable pearl is to disinfect in a pecking motion for thorough coverage. Proper framework follows ISO classifications to maintain air quality.

Question 12

A 61-year-old male (86 kg) with pulmonary embolism is ordered a heparin infusion prepared as 25,000 units in 250 mL of 0.45% sodium chloride. Allergies: none. Labs: SCr 1.0 mg/dL, AST 21 units/L, ALT 20 units/L, WBC 9,100/mm3^3, platelets 210,000/mm3^3. Current medications: aspirin 81 mg by mouth daily, atorvastatin 20 mg by mouth nightly. The infusion is compounded from a heparin vial into a minibag in an ISO Class 5 PEC and will be stored at room temperature for use within the day. What is the appropriate beyond-use date for this compound?

  1. 12 hours at controlled room temperature because it is a low-risk CSP (correct answer)
  2. 24 hours at controlled room temperature because it is a low-risk CSP
  3. 48 hours at controlled room temperature because it is a low-risk CSP
  4. 7 days at controlled room temperature because it is compounded in an ISO Class 5 PEC

Explanation: The concept being tested is beyond-use date (BUD) for low-risk compounded sterile preparations (CSPs) at room temperature. The key factor is room temperature storage of the heparin infusion compounded in an ISO Class 5 PEC for the pulmonary embolism patient. Choice A is the best because 12 hours at controlled room temperature adheres to low-risk guidelines, preventing coagulation issues and ensuring safety. Choice B is incorrect as 24 hours may exceed limits without specified conditions, risking instability. Choices C and D are suboptimal because 48 hours or 7 days overestimate for room temperature, common BUD errors. A transferable pearl is to label CSPs with BUD and storage requirements clearly. PPE guidelines emphasize double gloving for anticoagulants to avoid skin contact.

Question 13

A 70-year-old female (66 kg) with Clostridioides difficile infection is ordered fidaxomicin by mouth, but she cannot swallow; the team requests oral vancomycin solution prepared from vancomycin powder for injection reconstituted with sterile water and then further diluted for enteral administration. Allergies: none. Labs: SCr 1.2 mg/dL, AST 20 units/L, ALT 17 units/L, WBC 15,500/mm3^3. The pharmacy plans to compound the solution in the nonsterile compounding area. Which environmental condition is crucial for this preparation?

  1. An ISO Class 5 PEC is required because the source container is labeled for injection
  2. A negative-pressure hazardous buffer room is required because vancomycin is an antibiotic
  3. A nonsterile compounding area is acceptable because the final dosage form is intended for enteral administration, not parenteral use (correct answer)
  4. An ISO Class 7 buffer room is required for any preparation using sterile water for injection

Explanation: The concept being tested is appropriate environmental conditions for nonsterile preparations using sterile components. The key factor is the enteral administration of vancomycin solution prepared from injectable powder for the patient unable to swallow. Choice C is the best because nonsterile areas suffice for non-parenteral products, ensuring practicality without overclassifying and maintaining safety. Choice A is incorrect as ISO Class 5 is unnecessary for oral use, increasing costs. Choices B and D are suboptimal because negative pressure is for hazardous, and buffer rooms are for sterile preparations. A transferable pearl is to distinguish sterile vs. nonsterile based on route of administration. Proper technique includes accurate measuring for oral solutions to avoid dosing errors.

Question 14

A 43-year-old female (55 kg) with status epilepticus is ordered levetiracetam 1,500 mg IV once. Allergies: none. Labs: SCr 0.8 mg/dL, AST 17 units/L, ALT 14 units/L, WBC 11,000/mm3^3. Current medications: midazolam infusion, propofol infusion. A pharmacist observes a technician disinfecting vial stoppers with 70% isopropyl alcohol but immediately puncturing the stopper while it is still wet. What is the most critical step in preparing this sterile product?

  1. Allow the 70% isopropyl alcohol to dry completely to achieve effective disinfection before puncturing (correct answer)
  2. Use povidone-iodine instead of alcohol for vial stoppers to improve sporicidal activity
  3. Puncture the vial stopper multiple times to ensure adequate mixing of the drug
  4. Wipe the vial stopper with sterile water after alcohol to prevent coring

Explanation: The concept being tested is disinfection procedures in sterile compounding. The key factor is the technician puncturing a wet vial stopper, compromising disinfection for the levetiracetam dose in status epilepticus. Choice A is the best because allowing 70% isopropyl alcohol to dry ensures full antimicrobial action, maintaining sterility and patient safety. Choice B is incorrect as povidone-iodine is not standard for CSPs, potentially leaving residues. Choices C and D are suboptimal because multiple punctures increase coring, and water wiping reduces alcohol efficacy. A transferable pearl is to use friction rubs for at least 15 seconds during hand hygiene. Proper PPE includes sterile sleeves for arm protection in the PEC.

Question 15

A 27-year-old male (70 kg) with sickle cell pain crisis is ordered hydromorphone patient-controlled analgesia (PCA) syringe: hydromorphone 30 mg in 30 mL (1 mg/mL). Allergies: none. Labs: SCr 0.7 mg/dL, AST 24 units/L, ALT 20 units/L, WBC 13,000/mm3^3. Current medications: ketorolac 15 mg IV every 6 hours as needed, hydroxyurea 1,000 mg by mouth daily. The PCA syringe is compounded in an ISO Class 5 PEC in an ISO Class 7 buffer room. What is the most critical step in preparing this sterile product?

  1. Use a 0.22-micron filter on the final syringe to extend beyond-use date
  2. Independently verify the calculation and final concentration (1 mg/mL) before dispensing to prevent dosing error (correct answer)
  3. Prepare the syringe in the anteroom to reduce contamination of the buffer room
  4. Use the largest possible needle gauge to minimize coring of the vial stopper

Explanation: The concept being tested is verification steps in high-risk opioid compounding. The key factor is the concentrated hydromorphone PCA syringe, requiring accuracy to prevent overdose in the sickle cell patient. Choice B is the best because independent verification of calculation and concentration minimizes errors, ensuring safe pain management. Choice A is incorrect as filtering does not verify dosing, missing error prevention. Choices C and D are suboptimal because anteroom preparation violates classification, and large needles increase coring risks. A transferable pearl is to use double-checks for high-alert medications like opioids. Proper PPE includes gloves compatible with controlled substances.

Question 16

A 59-year-old female (68 kg) with breast cancer is ordered doxorubicin 60 mg IV today. Allergies: none. Labs: SCr 0.8 mg/dL, AST 30 units/L, ALT 27 units/L, total bilirubin 0.9 mg/dL, WBC 5,200/mm3^3. Current medications: dexamethasone 8 mg IV premedication, ondansetron 8 mg IV premedication. The pharmacy will compound the dose in an ISO Class 5 BSC located in a negative-pressure ISO Class 7 hazardous buffer room per USP <800>. What is the correct procedure to handle this hazardous drug?

  1. Prime the IV tubing with doxorubicin solution to avoid wasting diluent
  2. Use a closed-system drug-transfer device when possible and decontaminate the outer surface before leaving the hazardous buffer room (correct answer)
  3. Remove outer chemotherapy gloves inside the anteroom and keep inner gloves on for documentation in the clean area
  4. Compound in a standard positive-pressure ISO Class 7 buffer room to protect product sterility

Explanation: The concept being tested is safe handling procedures for hazardous drugs under USP <800>. The key factor is the hazardous classification of doxorubicin, requiring containment during compounding and transport for the breast cancer patient. Choice B is the best because using a closed-system drug-transfer device (CSTD) and decontaminating surfaces minimizes exposure risks, ensuring personnel and environmental safety. Choice A is incorrect as priming with drug wastes product and increases spill risk, a common hazardous handling error. Choices C and D are suboptimal because improper glove removal can spread contamination, and positive-pressure rooms are inappropriate for hazardous drugs. A transferable pearl is to always use CSTDs for hazardous drug administration to prevent leaks. Proper aseptic technique in BSCs includes vertical airflow to contain aerosols.

Question 17

A 62-year-old male (79 kg) with multiple myeloma is ordered cyclophosphamide 1,000 mg IV today (hazardous drug). Allergies: none. Labs: SCr 1.1 mg/dL, AST 26 units/L, ALT 24 units/L, WBC 3,200/mm3^3. Current medications: acyclovir 400 mg by mouth twice daily, allopurinol 300 mg by mouth daily. The dose will be compounded in a compounding aseptic containment isolator (CACI) located in a negative-pressure hazardous buffer room. Which personal protective equipment is required for this preparation?

  1. Two pairs of chemotherapy gloves and a chemotherapy gown; consider eye/face protection if splash risk exists (correct answer)
  2. Sterile gloves only, because a CACI provides complete containment and eliminates PPE requirements
  3. One pair of nonsterile gloves and a surgical mask only, because cyclophosphamide is not volatile
  4. N95 respirator and shoe covers only, because inhalation is the primary exposure route

Explanation: The sterile preparation concept being tested is the appropriate personal protective equipment (PPE) required for compounding hazardous drugs (HDs) in a compounding aseptic containment isolator (CACI). The key preparation-specific factor is that cyclophosphamide is a hazardous antineoplastic drug, posing risks of dermal, inhalation, and mucosal exposure during compounding. Choice A is the best choice for ensuring sterile integrity and patient safety because it mandates two pairs of chemotherapy gloves and a chemotherapy gown to minimize dermal absorption and contamination, while considering eye/face protection for splash risks as per USP <800> guidelines. Choice B is incorrect because a CACI provides containment but does not eliminate PPE needs, as exposure can occur from residues or breaches, a common error in assuming engineering controls suffice alone; choice C is suboptimal because one pair of nonsterile gloves and a mask offer inadequate barrier protection for HDs, risking occupational exposure; choice D is wrong because it prioritizes respiratory protection over comprehensive dermal safeguards, overlooking the primary exposure route for most HDs. A transferable sterile compounding pearl is to always layer engineering controls, administrative measures, and PPE for HD handling to prevent exposure. Proper PPE guidelines under USP <800> include donning in a specific order—gown, gloves, etc.—and doffing carefully to avoid contamination.

Question 18

A 60-year-old female (72 kg) with ovarian cancer is ordered paclitaxel 175 mg/m2^2 IV (hazardous drug) in a non-polyvinyl chloride (non-PVC) container. Allergies: none. Labs: SCr 0.9 mg/dL, AST 31 units/L, ALT 28 units/L, WBC 4,000/mm3^3. Current medications: diphenhydramine 50 mg IV, famotidine 20 mg IV, dexamethasone 20 mg IV as premedications. The dose will be compounded in an ISO Class 5 BSC in a negative-pressure ISO Class 7 hazardous buffer room. What is the correct procedure to handle this hazardous drug?

  1. Compound in a positive-pressure buffer room to protect the product from microbial contamination
  2. Use a closed-system drug-transfer device when possible and dispose of all materials as hazardous drug waste per facility policy (correct answer)
  3. Prepare outside the BSC if a non-PVC bag is used because it reduces exposure risk
  4. Wear sterile gloves only and omit chemotherapy gloves to reduce particulate shedding

Explanation: The concept being tested is handling procedures for hazardous drugs in non-PVC containers under USP <800>. The key factor is the hazardous classification of paclitaxel, requiring containment strategies during compounding for the ovarian cancer patient. Choice B is the best because using a CSTD and proper waste disposal minimizes exposure risks, promoting safety for personnel and environment. Choice A is incorrect as positive-pressure rooms allow contaminant escape, unsuitable for hazardous drugs. Choices C and D are suboptimal because preparing outside BSC or omitting chemo gloves increases risks, common handling errors. A transferable pearl is to use dedicated equipment for hazardous drugs. Proper aseptic technique in negative-pressure rooms protects both product and operator.

Question 19

A 58-year-old male (80 kg) receiving chemotherapy develops nausea and is ordered aprepitant IV (fosaprepitant) 150 mg infusion. Allergies: none. Labs: SCr 0.9 mg/dL, AST 33 units/L, ALT 29 units/L, WBC 3,800/mm3^3. Current medications: cisplatin, dexamethasone, ondansetron. The pharmacy is compounding the antiemetic infusion in an ISO Class 5 PEC in an ISO Class 7 buffer room (nonhazardous compounding suite). Which technique ensures sterility in this preparation?

  1. Arrange supplies to avoid blocking first air to critical sites and avoid working directly above open ports (correct answer)
  2. Work at the edge of the PEC to improve reach and visibility of the bag port
  3. Spray sterile 70% isopropyl alcohol into open syringe hubs to disinfect internal surfaces
  4. Use nonsterile gauze to wipe needle shafts before injection into the bag

Explanation: The concept being tested is workspace arrangement for aseptic technique in nonhazardous compounding. The key factor is preventing obstruction of first air during aprepitant infusion preparation for the chemotherapy patient. Choice A is the best because proper arrangement avoids blocking critical sites, ensuring HEPA air protection and product sterility. Choice B is incorrect as working at the edge reduces effective airflow, a common positioning error. Choices C and D are suboptimal because spraying into hubs or using nonsterile gauze introduces contaminants. A transferable pearl is to stage items from dirtiest to cleanest in the PEC. Proper aseptic framework involves visual inspection for particulates before dispensing.

Question 20

A 69-year-old male (83 kg) with heart failure is ordered a continuous IV infusion of bumetanide prepared as 12.5 mg in 50 mL 0.9% sodium chloride in a syringe for a pump. Allergies: none. Labs: SCr 2.0 mg/dL, AST 26 units/L, ALT 23 units/L, WBC 7,200/mm3^3. Current medications: carvedilol 12.5 mg by mouth twice daily, spironolactone 25 mg by mouth daily. The syringe is prepared in an ISO Class 5 PEC in an ISO Class 7 buffer room and will be refrigerated for use tomorrow. What is the appropriate beyond-use date for this compound?

  1. 48 hours refrigerated because it is a low-risk CSP (correct answer)
  2. 24 hours refrigerated because it is a low-risk CSP
  3. 7 days refrigerated because it is a single syringe preparation
  4. 12 hours refrigerated because it is a continuous infusion

Explanation: The concept being tested is beyond-use date (BUD) for low-risk compounded sterile preparations (CSPs) in syringes stored refrigerated. The key factor is refrigerated storage of the bumetanide syringe infusion prepared in an ISO Class 5 PEC for next-day use in heart failure. Choice A is the best because 48 hours refrigerated meets low-risk guidelines for syringe preparations, ensuring diuretic stability and patient safety. Choice B is incorrect as 24 hours is unnecessarily short, reducing efficiency. Choices C and D are suboptimal because 7 days or 12 hours do not align with risk level or storage. A transferable pearl is to protect syringes from light if drug-sensitive. Proper aseptic technique avoids overfilling to prevent pressure buildup.